Another strong LDHA inhibitor that has been thoroughly investigated in TNBC and ER +/PR + breast cancer is N-hydroxy indole (NHI), and FX- 11, a gossypol analog that targets LDHA, has been thoroughly investigated in ER +/PR + breast cancer [8, 9]. This evidence concerns the gene ESR1 and breast cancer.